KKR has agreed to acquire Integer Holdings Corporation in an all-cash transaction carrying an enterprise value of approximately $5.7 billion, extending the investment group’s healthcare portfolio into the specialised manufacturing infrastructure behind implantable and interventional medical devices.
Integer Holdings stockholders will receive $127 for each share under the definitive agreement announced on August 3, 2026. The consideration represents a 51.8% premium to the company’s closing value immediately before Integer Holdings announced a strategic review in April and a 28.8% premium to its 30-day volume-weighted average price through July 31.
The transaction is expected to close by the end of 2026, subject to approval from Integer Holdings stockholders, required regulatory clearances and other customary conditions. The agreement is not dependent on KKR obtaining financing, with the acquisition expected to be funded through KKR-managed investment funds and committed debt financing. Integer Holdings will become a privately owned company and leave the New York Stock Exchange after completion.
The deal places renewed attention on the contract development and manufacturing organisations that sit behind many of the world’s most sophisticated medical devices. Integer Holdings does not generally market its name directly to patients, but it designs and manufactures components, subsystems and finished products used by medical-technology companies across cardiovascular intervention, cardiac-rhythm management and neuromodulation.
KKR’s investment thesis appears to rest on the durability of those end markets and the difficulty of replacing a qualified manufacturing partner once a component has been incorporated into a regulated medical device. Integer Holdings’ near-term financial performance has weakened, however, leaving KKR to balance the company’s strategic position against slower growth, customer-programme transitions and more than $1.2 billion of debt.
Why is KKR paying $5.7 billion for medical-device manufacturer Integer Holdings?
Integer Holdings is one of the largest medical-device contract development and manufacturing organisations globally. It supports customers from early-stage product engineering and prototyping through component production, assembly and commercial-scale manufacturing.
Its capabilities are particularly relevant in categories where manufacturing errors can have serious consequences. Cardiac leads, catheters, implantable pulse-generator components, neurostimulation systems and vascular-delivery technologies must meet strict tolerances, biocompatibility requirements and regulatory quality standards.
A medical-device company can change a supplier, but such a transition may require engineering verification, process validation, regulatory documentation and, in some cases, approval of a manufacturing change. Those barriers can create long customer relationships and recurring demand for qualified manufacturers.
KKR described Integer Holdings as a differentiated platform with a global manufacturing footprint, established quality capabilities and exposure to durable healthcare markets. The investment firm indicated that it intends to provide capital and resources for additional capacity, technology, innovation and talent.
This gives KKR exposure to several medical-device manufacturers and product cycles through one company rather than requiring the firm to select a single implant, catheter or therapeutic platform. Integer Holdings can benefit when customers expand production of successful products, even when it does not own the underlying device brand.
The model also offers opportunities to acquire smaller specialised manufacturers and add their capabilities to Integer Holdings’ international network. A KeyBanc Capital Markets analyst told Reuters that Integer Holdings could operate as a platform through which KKR acquires and integrates additional assets.
What products and medical technologies does Integer Holdings manufacture?
Integer Holdings reports its operations primarily through the Cardio and Vascular and Cardiac Rhythm Management and Neuromodulation product lines.
The Cardio and Vascular business manufactures technologies used in structural-heart procedures, electrophysiology, peripheral and coronary vascular intervention, endoscopy and other catheter-based treatments. Its capabilities include metal components, guidewires, delivery systems, complex catheters and finished devices.
The Cardiac Rhythm Management and Neuromodulation business supports technologies such as pacemakers, defibrillators, cardiac leads, spinal-cord stimulation systems and other implantable neurostimulation devices. Integer Holdings may manufacture individual components, complete subsystems or finished devices depending on the customer programme.
This breadth is commercially important because the regulatory and engineering requirements differ considerably across these markets. A manufacturer capable of working with implantable batteries, precision metal parts, complex polymers, electrodes and minimally invasive delivery systems can support customers across several stages of a product’s development.
Integer Holdings has expanded its capabilities through acquisitions, including Pulse Technologies, which strengthened its precision-component manufacturing and development footprint in targeted medical-device markets. The company has argued that combining engineering and manufacturing capabilities can help customers reduce development times and move products into commercial production more efficiently.
KKR will gain a business with approximately 11,000 employees across its global operations. The investment firm plans to introduce a broad employee ownership and engagement programme after completing the acquisition, extending equity participation beyond senior management.
Why did Integer Holdings begin a strategic review before agreeing to the KKR deal?
Integer Holdings announced a comprehensive strategic review on April 30, 2026, saying its board would evaluate alternatives intended to maximise stockholder value. The review allowed the company to consider a sale, merger or continued operation as an independent public company.
The process followed pressure from Irenic Capital Management, which had accumulated a stake exceeding 3% and pushed for board changes and consideration of a sale. Integer Holdings reached a cooperation agreement with the activist investor in March and added two directors to its board.
The activist argument reflected a recurring difficulty for medical-device manufacturers operating behind well-known brands. Customer confidentiality can prevent a supplier from identifying individual programmes, commercial milestones or the companies using its components.
That limited disclosure can make it harder for public-market investors to understand the value of a manufacturer’s development pipeline. New programmes may require years of investment before entering commercial production, while delays or design changes can materially affect expected revenue without the supplier being able to discuss the customer publicly.
Private ownership could give Integer Holdings greater flexibility to invest through those programme cycles without facing the same quarterly scrutiny. KKR can also accept periods of slower profitability when it believes spending on facilities, technology or acquisitions will produce value over a longer investment horizon.
The Integer Holdings board ultimately concluded that KKR’s proposal offered the strongest combination of immediate value and strategic support following its review of available alternatives. The board approved the merger unanimously and recommended that stockholders support it.
What do Integer Holdings’ latest results reveal about the business KKR is acquiring?
Integer Holdings reported second-quarter 2026 sales of $464.1 million, representing a 2.6% decline from the corresponding period of 2025. Organic sales decreased by 1.5%.
Cardio and Vascular revenue fell by 2.3% to approximately $280.3 million. The company attributed part of the weakness to previously disclosed effects associated with two new electrophysiology products. Cardiac Rhythm Management and Neuromodulation revenue increased by 1% to approximately $173.7 million, although growth was partly offset by the effect of a new neuromodulation programme.
Revenue from other markets declined to approximately $10.1 million from $17.6 million, largely because of Integer Holdings’ strategic withdrawal from the portable-medical market.
Adjusted earnings before interest, tax, depreciation and amortisation declined by 4% to approximately $94.9 million. Adjusted operating income decreased by about 10%, while adjusted net income was broadly unchanged.
Total debt increased by $53 million from the end of 2025 to approximately $1.238 billion. Integer Holdings reported net debt of around $1.236 billion and a leverage ratio equivalent to 3.2 times adjusted earnings before interest, tax, depreciation and amortisation.
These figures explain why the acquisition is not simply a bet on uninterrupted growth. KKR is acquiring a strategically positioned company during a period of programme transitions, softer revenue and elevated leverage.
The opportunity is that some of those pressures may be temporary as customers scale newer products and Integer Holdings exits lower-priority activities. The risk is that delayed customer launches, pricing pressure or uneven demand persist longer than expected.
Integer Holdings withdrew its previous financial outlook after announcing the transaction and cancelled its scheduled August 6 earnings call.
How could private ownership change Integer Holdings’ medical-device investment strategy?
Medical-device manufacturing is capital intensive. New products may require dedicated production lines, specialised cleanrooms, automation, validation equipment and engineering teams before commercial revenue begins.
Public companies must justify that spending while meeting quarterly earnings expectations. Private ownership can provide greater flexibility when investments require several years to mature.
KKR has indicated that Integer Holdings will receive capital to expand capacity, develop technology and increase innovation. The most valuable investment areas are likely to include facilities supporting fast-growing structural-heart, electrophysiology, neurostimulation and minimally invasive procedural markets.
Automation may become another priority. Medical-device manufacturing often combines highly specialised manual processes with precision machining, laser processing, coating and inspection. Greater automation can improve repeatability and productivity, but implementing it requires capital and extensive validation.
KKR could also use Integer Holdings as a consolidation platform. Smaller medical-device suppliers frequently possess valuable expertise in a narrow technology but lack the global manufacturing scale or customer access required to grow independently.
Adding these businesses to Integer Holdings could broaden its engineering capabilities and increase the amount of each customer’s product that the company can manufacture. The strategy could also deepen customer dependency by allowing Integer Holdings to support a device from initial design through full commercial production.
That opportunity brings integration risk. Acquired companies can have different quality systems, production cultures and customer commitments. Poor integration could delay programmes or create compliance problems in a sector where reliability is more important than rapid cost cutting.
Why is private equity showing greater interest in medical-device companies?
The Integer Holdings acquisition forms part of a broader wave of private-equity investment across medical technology and diagnostics.
Recent transactions have included American Industrial Partners’ acquisition of Avanos Medical and the Blackstone and TPG agreement to acquire Hologic. Reuters reported that KKR’s Integer Holdings transaction is viewed by some analysts as evidence that private-equity firms continue to see value in established medtech businesses affected by temporary public-market headwinds.
Medical-device businesses can appeal to private equity because they often generate recurring revenue from consumables, replacement components and established clinical procedures. Regulatory barriers, surgeon training and long qualification cycles can also make it difficult for new competitors to enter.
Contract manufacturers have an additional attraction. They can participate in the growth of several device categories without assuming all the clinical-development and commercial risk associated with owning an individual product.
An outsourced manufacturer may also benefit as medical-device companies seek to reduce internal fixed costs and rely on specialised partners. Smaller innovators frequently need a manufacturer capable of helping them transition from prototype production to regulated commercial scale.
The risks should not be overlooked. Medical-device suppliers face customer concentration, price negotiations, quality audits, supply-chain disruption and the possibility that a customer’s product fails clinically or commercially.
Private-equity ownership can add financial leverage to those operating risks. KKR will therefore need to avoid creating a capital structure that restricts Integer Holdings’ ability to maintain quality, support customers and invest in capacity.
What could the takeover mean for Integer Holdings’ medical-device customers?
Customers will initially look for continuity. Medical-device companies rely on suppliers to deliver validated components according to precise specifications and production schedules.
A change in ownership should not alter those obligations, but customers may seek assurances concerning management retention, investment priorities, facility plans and long-term supply commitments.
KKR’s willingness to fund capacity could be beneficial when customers are preparing major launches or increasing production. A larger investment budget could reduce bottlenecks and allow Integer Holdings to respond more quickly to demand.
Customers may also gain access to a wider range of services if KKR supports acquisitions that expand Integer Holdings’ technologies. A manufacturer capable of offering engineering, precision components, catheters, implantable systems and final assembly can simplify a customer’s supply chain.
The concern is that private-equity ownership may eventually produce pressure for higher margins, restructuring or changes in commercial terms. Medical-device customers may resist price increases where a component is already qualified and expensive to transfer.
The best outcome would involve KKR improving efficiency and expanding capacity without weakening Integer Holdings’ engineering depth or quality culture. In medical-device manufacturing, financial returns are ultimately dependent on operational reliability.
What regulatory and execution risks could still delay the KKR acquisition?
The transaction requires approval from Integer Holdings stockholders and applicable regulators. It is expected to close by the end of 2026, but the timing is not guaranteed.
Antitrust risk may be more limited than in a combination between two major branded device manufacturers because KKR is an investment firm and Integer Holdings is a contract manufacturer. Regulators may nevertheless examine KKR’s existing healthcare holdings and any potential overlap involving medical-device manufacturing or supply relationships.
Financing risk is reduced because the agreement does not contain a financing condition, although KKR still intends to use a combination of fund equity and committed debt.
Stockholder litigation is possible, particularly around the sale process, valuation or disclosure of competing alternatives. The relatively small premium over Integer Holdings’ market value immediately before the deal announcement may also attract scrutiny, although the consideration is substantially above the value preceding the strategic review.
Operational disruption represents a more immediate concern. Employees, customers and suppliers may delay decisions while waiting for clarity about future ownership, leadership and investment plans.
Integer Holdings must also retain the engineers, quality specialists and manufacturing personnel responsible for customer programmes. Losing technical employees during the transition could damage relationships that KKR is paying to acquire.
KKR is buying the infrastructure behind medtech innovation, not a single device
The strategic logic of the Integer Holdings acquisition is stronger than the company’s latest quarterly growth figures might initially suggest.
Integer Holdings occupies a valuable position between medical-device invention and commercial production. Its customers may own the brands, clinical evidence and regulatory approvals, but those products cannot reach patients without reliable engineering and manufacturing.
This makes Integer Holdings a picks-and-shovels investment in cardiovascular and neuromodulation innovation. KKR gains exposure to several device categories, customers and development pipelines while reducing dependence on the success of one branded platform.
The timing is also notable. Integer Holdings’ slowing sales, customer-product transitions and higher debt created the conditions for a strategic review, while the company’s long-term capabilities remained attractive.
Taking the business private could allow KKR to invest through the current slowdown, expand high-value production capacity and acquire smaller specialist manufacturers. That strategy could produce a stronger medical-device platform when customer programmes move into higher-volume production.
The principal risk is that private ownership becomes primarily a financial-engineering exercise. Integer Holdings’ value depends on quality systems, engineering knowledge, customer trust and patient safety. Excessive leverage or aggressive cost reduction could damage the very characteristics that justify the acquisition.
KKR appears to recognise that the opportunity lies in long-term industrial development rather than a rapid restructuring. Its promised investment in technology, capacity and employee ownership supports that interpretation, although execution after closing will matter more than acquisition-day language.
For the broader medical-device industry, the deal reinforces the strategic importance of outsourced development and manufacturing. The companies that manufacture the smallest components are increasingly becoming some of the largest acquisition targets.
